B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
- The report reviews pipeline therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAbclon Inc
Achelois BioPharma Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Amgen Inc
Anhui Provincial Hospital of Chinese Medicine
Arovella Therapeutics Ltd
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
Athenex Inc
Autolus Therapeutics Plc
Auxi Therapeutics Sdn Bhd
Avalon GloboCare Corp
AVM Biotechnology LLC
Bambino Gesu Hospital and Research Institute
Beijing Boren Hospital
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Tongren Hospital
Bellicum Pharmaceuticals Inc
Bioceltech Therapeutics Ltd
Biohaven Ltd
BRL Medicine Inc
Capital Medical University
CARGO Therapeutics Inc
Cellectis SA
Cellex Gesellschaft fur Zellgewinnung mbH
Century Therapeutics Inc
Ceptur Therapeutics Inc
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu USino Technology Biology Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Children’s Hospital of Fudan University
China Immunotech (Beijing) Biotechnology Co Ltd
China Immunotech Co Ltd
Chongqing Precision Biotech Co Ltd
City of Hope
CoImmune Inc
CRISPR Therapeutics AG
Cullinan Oncology Inc
Curon Biopharmaceutical Ltd
CytoCares Shanghai Inc
Dalian Medical University
Dmitry Rogachev National Research Center of Pediatric Hematology
Oncology and Immunology
EdiGene Inc
Elf Zone Inc
Enzyme by Design Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fochon Pharmaceutical Ltd
Fosun Kite Biotechnology Co Ltd
Gansu Provincial Cancer Hospital
Genenta Science SpA
Genentech USA Inc
General Hospital of the People's Liberation Army
Generium
Gilead Sciences Inc
Gracell Biotechnologies Inc
Guangdong Second Provincial General Hospital
Guangdong Zhaotai Cell Biotechnology Co Ltd
Guangzhou Bio-gene Technology Co Ltd
Hangzhou Qihan Biotechnology Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hebei Yanda Hospital
Henan Cancer Hospital
Henan Honghui Biotechnology Co Ltd
HRAIN Biotechnology Co Ltd
Huadao Shanghai Biomedical Co Ltd
iCell Gene Therapeutics LLC
Immuneel Therapeutics Pvt Ltd
Immunotech Biopharm Ltd
Imugene Ltd
Innate Pharma SA
Institute of Hematology and Blood Transfusion
ITabMed Co Ltd
Jenthera Therapeutics Inc
Jilin University
Johnson & Johnson
Juventas Cell Therapy Ltd
JW Cayman Therapeutics Co Ltd
Kecellitics Biotech Co Ltd
KK Women's and Children's Hospital
Kunming Medical University
Legend Biotech Corp
Leman Biotech Co Ltd
Les Laboratoires Servier SAS
Loyola University Chicago
Luoyang Central Hospital
MacroGenics Inc
ManysmarT Therapeutics Inc
Maru Therapeutics Co Ltd
Miltenyi Biomedicine GmbH
Nagoya University Hospital
Nanfang Hospital
Nanfang Hospital of Southern Medical University
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing IASO Biotherapeutics Co Ltd
National University of Malaysia
Nationwide Children's Hospital
Navy General Hospital
Nektar Therapeutics
Newave Pharmaceutical Inc
Nkarta Inc
Novartis AG
NovoMedix LLC
Ohio State University Comprehensive Cancer Center
OneChain Immunotherapeutics
Orca Biosystems Inc
Orgenesis Inc
Oslo University Hospital
PeproMene Bio Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Precigen Inc
Puretech Health Plc
Saban Research Institute of Childrens Hospital Los Angeles
Second Affiliated Hospital of Shanxi Medical University
Shandong University
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Jiao Tong University School of Medicine
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Longyao Biotechnology Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pudong Hospital
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Pregene Biopharma Co Ltd
Shenzhen Second People's Hospital
Shenzhen University General Hospital
Sichuan University
SinoCelltech Group Ltd
SooChow University
Stanford University
Sunnycell Therapeutics Ltd
Suzhou Fundamenta Therapeutics Co Ltd
Systimmune Inc
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Tianjin Mycure Medical Technology Co Ltd
University of Colorado Denver
University of Minnesota
University of Sao Paulo
University of Texas MD Anderson Cancer Center
Vincerx Pharma Inc
Vinmec Research Institute of Stem Cell and Gene Technology
Wellington Zhaotai Therapies Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xencor Inc
Xiamen Nuokang Biotechnology Co Ltd
Xuanwu Hospital Capital Medical University
Xuzhou Medical University
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang University
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd